Loading...
XNAS
DXCM
Market cap25bUSD
Dec 04, Last price  
65.25USD
1D
0.62%
1Q
-18.95%
Jan 2017
337.19%
IPO
2,446.34%
Name

Dexcom Inc

Chart & Performance

D1W1MN
XNAS:DXCM chart
P/E
44.30
P/S
6.33
EPS
1.47
Div Yield, %
—
Shrs. gr., 5y
2.25%
Rev. gr., 5y
22.27%
Revenues
4.03b
+11.34%
02,169,7904,627,0009,838,00029,693,00048,631,00076,266,00099,900,000160,000,000259,200,000402,000,000573,300,000718,500,0001,031,600,0001,476,000,0001,926,700,0002,448,500,0002,909,800,0003,622,300,0004,033,000,000
Net income
576m
+6.41%
-30,767,430-46,599,291-45,878,000-55,184,000-53,524,000-55,170,000-44,746,000-54,500,000-29,800,000-22,400,000-57,600,000-65,600,000-50,200,000-127,100,000101,100,000493,600,000154,700,000341,200,000541,500,000576,200,000
CFO
990m
+32.20%
-22,553,785-43,734,840-33,207,000-37,451,000-39,389,000-42,676,000-30,126,000-33,100,0002,400,00023,600,00049,000,00056,200,00092,000,000123,200,000314,500,000475,600,000442,500,000669,500,000748,500,000989,500,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
URL
https://www.dexcom.com/
IPO date
Apr 14, 2005
Employees
7,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT